Rebrand to Rein Therapeutics is representative
of the Company's sole focus in developing therapies in orphan
pulmonary and fibrosis indications, including two Phase 2-ready
clinical assets
Company shares to begin trading on Nasdaq
under the trading symbol "RNTX" effective January 13, 2025
AUSTIN,
Texas, Jan. 10, 2025 /PRNewswire/ -- Rein
Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron
Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical
company advancing a novel pipeline of first-in-class medicines to
address significant unmet medical needs in orphan pulmonary and
fibrosis indications, today announced that it has changed its name
to Rein Therapeutics, Inc. The new name, logo, website, and
branding elements reflect the Company's mission to develop
first-in-class treatments to rein in diseases. The Company's common
stock will begin trading under the Nasdaq ticker symbol "RNTX"
effective January 13, 2025. The CUSIP
number for the Company's common stock is not affected by the name
change. The Company also highlighted its recent clinical and
corporate achievements and provided its key strategic objectives
for 2025.
"Our rebrand to Rein Therapeutics reflects our unwavering
commitment to address the critical needs of underserved patients
with fibrotic diseases," said Brian
Windsor, Ph.D., President and Chief Executive Officer. "This
new chapter for the Company underscores our focus on reining in
fibrosis and advancing our pipeline of novel candidates. We look
forward to the initiation of a Phase 2 clinical trial for our lead
candidate, LTI-03, in the first half of this year, aiming to bring
hope to those affected by idiopathic pulmonary fibrosis."
Recent Clinical Achievements
- LTI-03, a Caveolin-1 related
peptide:
- In November 2024, the Company
announced positive topline data from Cohort 2 of the Phase
1b clinical trial evaluating the
safety and tolerability of inhaled high dose LTI-03 (5 mg BID) and
a set of exploratory biomarkers in patients with idiopathic
pulmonary fibrosis (IPF). Four biomarkers showed statistical
significance in the combined Cohort 1 and Cohort 2 dataset, and
five demonstrated dose dependence with respect to low dose (2.5 mg
BID) Cohort 1, indicative of active pharmacodynamics. High dose
LTI-03 continued to exhibit a favorable safety profile.
- 2024 Corporate Highlights:
- In March 2024, Brian Windsor, Ph.D., was appointed Chief
Executive Officer of the Company, marking the Company's sole focus
on advancing a pipeline of first-in-class therapies for orphan
pulmonary and fibrosis indications.
- In May 2024, the Company
completed an underwritten registered direct offering of its common
stock and accompanying warrants raising net proceeds of
approximately $17.7 million.
2025 Strategic Objectives and Anticipated Milestones
- LTI-03: A Phase 2 trial of LTI-03 for the treatment of
IPF is anticipated to be initiated in the first half of this
year.
- LTI-01: The Company's Phase 2b-ready asset is a first-in-class therapy for
the treatment of loculated pleural effusions (LPEs). It holds
Orphan Drug Designation for the treatment of pleural empyema in the
U.S and E.U. and Fast Track Designation in the U.S.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical
company advancing a novel pipeline of first-in-class therapies to
address significant unmet medical needs in orphan pulmonary and
fibrosis indications. Rein's lead product candidate, LTI-03, is a
novel, synthetic peptide with a dual mechanism targeting alveolar
epithelial cell survival as well as inhibition of profibrotic
signaling. A Phase 2 clinical trial of LTI-03 for the treatment of
idiopathic pulmonary fibrosis is anticipated to be initiated in the
first half of this year. Rein's second product candidate, LTI-01,
is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment
of loculated pleural effusions. LTI-01 has received Orphan Drug
Designation in the U.S. and E.U. and Fast Track Designation in the
U.S. For more information, please visit the company's website at
reintx.com, or follow them on LinkedIn and X.
Forward-Looking Statements
This press release may contain forward-looking statements of
Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or
"us") within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements with respect to: the
timing and expectation of a Phase 2 trial of LTI-03; and future
expectations, plans and prospects for the Company. We use words
such as "anticipate," "believe," "estimate," "expect," "hope,"
"intend," "may," "plan," "predict," "project," "target,"
"potential," "would," "can," "could," "should," "continue," and
other words and terms of similar meaning to help identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
risks and uncertainties related to: changes in applicable laws or
regulations; the possibility that the Company may be adversely
affected by other economic, business, and/or competitive factors,
including risks inherent in pharmaceutical research and
development, such as: adverse results in the Company's drug
discovery; preclinical and clinical development activities; the
risk that the results of preclinical studies and early clinical
trials may not be replicated in later clinical trials, including in
a Phase 2 trial of LTI-03, or that partial results of a trial
will be indicative of the full results of the trial; the Company's
ability to enroll patients in its clinical trials; and the risk
that any of its clinical trials may not commence, continue or be
completed on time, or at all; decisions made by the U.S. Food and
Drug Administration and other regulatory authorities;
investigational review boards at clinical trial sites and
publication review bodies with respect to the our development
candidates; our ability to obtain, maintain and enforce
intellectual property rights for our platform and development
candidates; competition; the sufficiency of the Company's cash
resources to fund its planned activities for the periods
anticipated and the Company's ability to manage unplanned cash
requirements; and general economic and market conditions; as well
as the risks and uncertainties discussed in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2023, and the
Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are on file with the
United States Securities and Exchange Commission (the "SEC") and in
subsequent filings that the Company files with the SEC. These
forward-looking statements should not be relied upon as
representing the Company's view as of any date subsequent to the
date of this press release, and we expressly disclaim any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Rein Investor Relations & Media Contact
Argot
Partners
rein@argotpartners.com
212-600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-rebranding-to-rein-therapeutics-302348094.html
SOURCE Rein Therapeutics, Inc.